PhaseBio Pharmaceuticals CEO Jonathan Mow's 2021 pay slips 13% to $1.5M
PhaseBio Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: April 22, 2022
PhaseBio Pharmaceuticals reported fiscal year 2021 executive compensation information on April 22, 2022.
In 2021, three executives at PhaseBio Pharmaceuticals received on average a compensation package of $1.1M, a 10% decrease compared to previous year.
Average pay of disclosed executives at PhaseBio Pharmaceuticals
Jonathan P. Mow, Chief Executive Officer, received $1.5M in total, which decreased by 13% compared to 2020. 41% of Mow's compensation, or $634K, was in option awards. Mow also received $319K in non-equity incentive plan, $562K in salary, as well as $14K in other compensation.
John Lee, Chief Medical Officer, received a compensation package of $856K, which decreased by 6% compared to previous year. 52% of the compensation package, or $443K, was in salary.
John P. Sharp, Chief Financial Officer, earned $781K in 2021, a 8% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on April 22, 2022.